Document Detail


Briakinumab.
MedLine Citation:
PMID:  19569977     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Psoriasis is a chronic, autoimmune, T-cell mediated, inflammatory disease. An improved understanding of the pathogenesis of the autoimmune response has led to the development of targeted biologic therapies. Briakinumab is a human monocolonal antibody that blocks the activity of the cytokines IL-12 and IL-23. Immune dysregulation has been implicated in multiple inflammatory disorders and briakinumab has been investigated for the treatment of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. OBJECTIVES: This review focuses on briakinumab and its use in chronic plaque-type psoriasis. METHODS: A literature review was performed, searching Medline and the clinicaltrials.gov database for all articles with the keywords ABT-874, IL-12/IL-23 and psoriasis. CONCLUSIONS: Although limited by small sample sizes, length of follow-up, and a lack of direct comparisons with other psoriasis treatments, initial data regarding the safety and efficacy of briakinumab for the treatment of psoriasis is promising. Ongoing Phase III trials may provide additional information regarding the relative efficacy and safety of briakinumab.
Authors:
Xinaida Taligare Lima; Katrina Abuabara; Alexandra Boer Kimball; Hermenio Cavalcante Lima
Related Documents :
20003607 - Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy.
1503497 - The interleukin-2 receptor in lesions and serum of bullous pemphigoid.
20180637 - Kallikrein-related peptidases: bridges between immune functions and extracellular matri...
19342087 - Uv-b radiation induces the expression of antimicrobial peptides in human keratinocytes ...
19590527 - The cytotoxic macrolide fd-891 induces caspase-8-dependent mitochondrial release of cyt...
7442587 - Control of ovarian function by the immune system: is this a plausible and necessary hyp...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  9     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-07-13     Completed Date:  2009-11-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1107-13     Citation Subset:  IM    
Affiliation:
Massachusetts General Hospital - Harvard Medical School, Boston, MA 02114, USA. xlima@partners.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Monoclonal / therapeutic use*
Biological Therapy / methods
Clinical Trials as Topic
Humans
Immunologic Factors / therapeutic use
Inflammation
Interleukin-12 / metabolism
Interleukin-23 / metabolism
Models, Biological
Psoriasis / drug therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunologic Factors; 0/Interleukin-23; 0/briakinumab; 187348-17-0/Interleukin-12

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet...
Next Document:  Vesicular carriers for dermal drug delivery.